|
Volumn 174, Issue 5, 2001, Pages 302-303
|
Op-Ed: The cost to global health of drug company profits: These profits are made on the losses of vulnerable people
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DRUG INDUSTRY;
DRUG MARKETING;
DRUG SCREENING;
DRUG SURVEILLANCE PROGRAM;
HEALTH CARE COST;
PROFIT;
RESPONSIBILITY;
SHORT SURVEY;
UNITED STATES;
ECONOMICS;
EDITORIAL;
ETHICS;
FEMALE;
HEALTH;
HEALTH CARE AND PUBLIC HEALTH;
HUMAN;
MALE;
RISK ASSESSMENT;
HEALTH CARE AND PUBLIC HEALTH;
DRUG INDUSTRY;
ETHICS;
FEMALE;
HUMANS;
MALE;
RISK ASSESSMENT;
WORLD HEALTH;
|
EID: 0035344236
PISSN: 00930415
EISSN: None
Source Type: Journal
DOI: 10.1136/ewjm.174.5.302 Document Type: Short Survey |
Times cited : (8)
|
References (12)
|